Afghanistan vs Indonesia: The number of people with susceptibility test result for rifampicin
Afghanistan
70.58
in 2021
Indonesia
72.55
in 2021
Afghanistan rank
103rd
Indonesia rank
102nd
The number of people with susceptibility test result for rifampicin over time
- Afghanistan
- Indonesia
How they compare
Indonesia currently reports 72.55 against 70.58 in Afghanistan, a difference of 1.97.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Afghanistan ahead.
Afghanistan ranks 103rd and Indonesia ranks 102nd of 146 countries.
Indonesia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Afghanistan | Indonesia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 28.75 | 30.84 | 2.09 | Indonesia |
| 2020s | 57.72 | 65.06 | 7.34 | Indonesia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Afghanistan or Indonesia?
- Indonesia, at 72.55 against 70.58 in Afghanistan as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Afghanistan and Indonesia?
- 1.97, with Indonesia ahead.
- How many years of comparable data are there for Afghanistan and Indonesia?
- 5 years are reported by both, from 2017 to 2021.
- How do Afghanistan and Indonesia rank globally for the number of people with susceptibility test result for rifampicin?
- Afghanistan ranks 103rd and Indonesia ranks 102nd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.